Cargando…

N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients

It is unclear whether N-acetylaspartate (NAA) depletions documented in schizophrenia patients might be due to the disease progression or medications. Here we investigated longitudinal NAA changes in drug-naïve first-episode patients (FEP) who are relatively free from chronicity. Forty-two drug-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Xiaofen, Hu, Maolin, Li, Zongchang, Cao, Hongbao, He, Ying, Liao, Yanhui, Zhou, Jun, Sang, Deen, Zhao, Hongzeng, Tang, Jinsong, Lv, Luxian, Chen, Xiaogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894446/
https://www.ncbi.nlm.nih.gov/pubmed/25778460
http://dx.doi.org/10.1038/srep09109
_version_ 1782435679785975808
author Zong, Xiaofen
Hu, Maolin
Li, Zongchang
Cao, Hongbao
He, Ying
Liao, Yanhui
Zhou, Jun
Sang, Deen
Zhao, Hongzeng
Tang, Jinsong
Lv, Luxian
Chen, Xiaogang
author_facet Zong, Xiaofen
Hu, Maolin
Li, Zongchang
Cao, Hongbao
He, Ying
Liao, Yanhui
Zhou, Jun
Sang, Deen
Zhao, Hongzeng
Tang, Jinsong
Lv, Luxian
Chen, Xiaogang
author_sort Zong, Xiaofen
collection PubMed
description It is unclear whether N-acetylaspartate (NAA) depletions documented in schizophrenia patients might be due to the disease progression or medications. Here we investigated longitudinal NAA changes in drug-naïve first-episode patients (FEP) who are relatively free from chronicity. Forty-two drug-naïve FEP and 38 controls were enrolled in this study to explore the effect of 8-week risperidone monotherapy on NAA. All spectra were obtained from the medial prefrontal cortex (MPFC) on a 3.0 T MRI and analyzed with LCModel. At baseline, patients presented no significant differences in NAA (P = 0.084) or NAA/Cr + Pcr (P = 0.500) compared to controls; NAA levels were negatively correlated with PANSS total scores (P = 0.001) and WCST-PE (P = 0.041). After treatment, patients demonstrated significant reductions of NAA (P < 0.001) and NAA/Cr + Pcr (P < 0.001), and significant improvement in PANSS-P (P < 0.001) and PANSS-G (P < 0.001) symptoms. We detected no significant correlations between NAA alterations and PANSS-P (P = 0.679) or PANSS-G (P = 0.668) symptom changes; nor did NAA/Cr + Pcr changes with alterations in PANSS-P (P = 0.677) and PANSS-G (P = 0.616). This is the first evidence that short-term risperidone treatment induces an acute reduction of MPFC NAA during the early phase of schizophrenia, which may be a previously unavailable biomarker to indicate risperidone with a similar pharmacological mechanism, although the functional significance is still unclear.
format Online
Article
Text
id pubmed-4894446
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48944462016-06-10 N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients Zong, Xiaofen Hu, Maolin Li, Zongchang Cao, Hongbao He, Ying Liao, Yanhui Zhou, Jun Sang, Deen Zhao, Hongzeng Tang, Jinsong Lv, Luxian Chen, Xiaogang Sci Rep Article It is unclear whether N-acetylaspartate (NAA) depletions documented in schizophrenia patients might be due to the disease progression or medications. Here we investigated longitudinal NAA changes in drug-naïve first-episode patients (FEP) who are relatively free from chronicity. Forty-two drug-naïve FEP and 38 controls were enrolled in this study to explore the effect of 8-week risperidone monotherapy on NAA. All spectra were obtained from the medial prefrontal cortex (MPFC) on a 3.0 T MRI and analyzed with LCModel. At baseline, patients presented no significant differences in NAA (P = 0.084) or NAA/Cr + Pcr (P = 0.500) compared to controls; NAA levels were negatively correlated with PANSS total scores (P = 0.001) and WCST-PE (P = 0.041). After treatment, patients demonstrated significant reductions of NAA (P < 0.001) and NAA/Cr + Pcr (P < 0.001), and significant improvement in PANSS-P (P < 0.001) and PANSS-G (P < 0.001) symptoms. We detected no significant correlations between NAA alterations and PANSS-P (P = 0.679) or PANSS-G (P = 0.668) symptom changes; nor did NAA/Cr + Pcr changes with alterations in PANSS-P (P = 0.677) and PANSS-G (P = 0.616). This is the first evidence that short-term risperidone treatment induces an acute reduction of MPFC NAA during the early phase of schizophrenia, which may be a previously unavailable biomarker to indicate risperidone with a similar pharmacological mechanism, although the functional significance is still unclear. Nature Publishing Group 2015-03-16 /pmc/articles/PMC4894446/ /pubmed/25778460 http://dx.doi.org/10.1038/srep09109 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Zong, Xiaofen
Hu, Maolin
Li, Zongchang
Cao, Hongbao
He, Ying
Liao, Yanhui
Zhou, Jun
Sang, Deen
Zhao, Hongzeng
Tang, Jinsong
Lv, Luxian
Chen, Xiaogang
N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title_full N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title_fullStr N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title_full_unstemmed N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title_short N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
title_sort n-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894446/
https://www.ncbi.nlm.nih.gov/pubmed/25778460
http://dx.doi.org/10.1038/srep09109
work_keys_str_mv AT zongxiaofen nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT humaolin nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT lizongchang nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT caohongbao nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT heying nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT liaoyanhui nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT zhoujun nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT sangdeen nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT zhaohongzeng nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT tangjinsong nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT lvluxian nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients
AT chenxiaogang nacetylaspartatereductioninthemedialprefrontalcortexfollowing8weeksofrisperidonetreatmentinfirstepisodedrugnaiveschizophreniapatients